Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 8935 results

  1. WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]

    Awaiting development Reference number: GID-TA11305 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]

    Awaiting development Reference number: GID-TA11417 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]

    Awaiting development Reference number: GID-TA11050 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]

    Awaiting development Reference number: GID-TA11271 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development Reference number: GID-TA11438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development Reference number: GID-TA11360 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development Reference number: GID-TA11284 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development